Edesa Biotech, Inc. (EDSA)

Market Cap	7.14M
Revenue (ttm)	n/a
Net Income (ttm)	-6.93M
Shares Out	3.25M
EPS (ttm)	-2.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,612
Open	2.240
Previous Close	2.190
Day's Range	2.050 - 2.240
52-Week Range	2.050 - 6.460
Beta	0.84
Analysts	Strong Buy
Price Target	21.00 (+854.55%)
Earnings Date	Dec 13, 2024

About EDSA

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic cont...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: EDSA
• Website: https://www.edesabiotech.com

Analyst Forecast

According to one analyst, the rating for EDSA stock is "Strong Buy" and the 12-month stock price forecast is $21.0.

Price Target

$21.0

(854.55% upside)

Analyst Consensus: Strong Buy